Cipla's InvaGen Receives USFDA Inspection Clearance for Long Island Manufacturing Facility
Cipla Limited has received confirmation that its subsidiary, InvaGen Pharmaceuticals, Inc., has closed out a critical inspection process with the United States Food and Drug Administration (USFDA). The Establishment Inspection Report (EIR) was granted by the USFDA following the Pre-Approval Inspection (PAI) conducted at InvaGen's manufacturing facility.InvaGen Pharmaceuticals, which is a wholly-owned subsidiary of Cipla Limited, is located in Hauppauge, Long Island, New York, USA. The successful receipt of the EIR signifies the closure of the inspection following the PAI conducted by the USFDA at the American facility.
CIPLA Stock Price Movement
As of the 9:00 AM pre-open session, CIPLA LIMITED shares show firm interest trading near the ₹1398.70 mark, indicating buyer strength in this early phase. The equity remains highly volatile within its range and faces historical pressure, as it is noted that the stock once plunged to its 52-week low during previous cycles.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.